The Private Equity team advised Nexelis, the Quebec-based provider of clinical immunology laboratory services, and its shareholder, the middle-market private equity firm, Ampersand Capital Partners, on the acquisition of Belgium-based ImmunXperts.
ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in vitro functional and potency assays. These assays help pharmaceutical and biotech sponsors screen, select and optimize lead compounds before the initiation of in vivo trials.
The Goodwin team was led by partner William Robert and included James Barrett, Ed Amer and Brett Jackson, Daniel Karelitz and Nicole Spiteri.
For more information, read the press release.